Aptargroup Inc.

AptarGroup is a supplier of a range of dispensing, sealing and active packaging solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets. The company's primary products are dispensing pumps, which dispense a spray or lotion from non-pressurized containers; closures, which are plastic caps that allow a product to be dispensed without removing the cap; aerosol valves, which dispense product from pressurized containers; and elastomeric primary packaging components, which include stoppers for infusion, antibiotic, lyophilization and diagnostic vials, pre-filled syringe components, as well as dropper bulbs and syringe plungers.
  • TickerATR
  • ISINUS0383361039
  • ExchangeNew York Stock Exchange
  • SectorGeneral Industrials
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

Charles Gross

Morningstar | Aptar Adds Capabilities to Its Competitively Advantaged Pharma Business; Raising FVE to $92

On June 10, Aptar announced its acquisition of Nanopharm and Gateway Analytical, two small pharma-oriented businesses that facilitate new product development. The move is compelling in our eyes, with potential long-term benefits that should easily exceed the fairly modest $50 million purchase price. Not only could this help to elongate the competitive advantages enjoyed by Aptar, but we also expect it to increase midcycle margins in the pharma segment. We've increased our fair value estimate to $92 per share from $89, and our narrow-moat rating is unchanged. Adding auxiliary services that red...

Charles Gross

Morningstar | Aptar Adds Capabilities to Its Competitively Advantaged Pharma Business; Raising FVE to $92. See Updated Analyst Note from 11 Jun 2019

On June 10, Aptar announced its acquisition of Nanopharm and Gateway Analytical, two small pharma-oriented businesses that facilitate new product development. The move is compelling in our eyes, with potential long-term benefits that should easily exceed the fairly modest $50 million purchase price. Not only could this help to elongate the competitive advantages enjoyed by Aptar, but we also expect it to increase midcycle margins in the pharma segment. We've increased our fair value estimate to $92 per share from $89, and our narrow-moat rating is unchanged. Adding auxiliary services that red...

Charles Gross

Aptar Adds Capabilities to Its Competitively Advantaged Pharma Business; Raising FVE to $92

On June 10, Aptar announced its acquisition of Nanopharm and Gateway Analytical, two small pharma-oriented businesses that facilitate new product development. The move is compelling in our eyes, with potential long-term benefits that should easily exceed the fairly modest $50 million purchase price. Not only could this help to elongate the competitive advantages enjoyed by Aptar, but we also expect it to increase midcycle margins in the pharma segment. We've increased our fair value estimate to ...

Charles Gross

Morningstar | ATR Updated Forecasts and Estimates from 15 May 2019

Aptar is the global leader in resin-based dispensing technologies. Its aversion to low-margin bottle forming has allowed Aptar to focus on the more lucrative production of items like fragrance pumps, respiratory inhalers, and food and beverage closures. Patented designs and high regulatory switching costs have allowed Aptar to earn excess return on invested capital, while revenue growth has been spurred by increased health spending and a consumer preference for convenience. The pharmaceutical segment is Aptar's core earnings growth driver. It delivers almost two thirds of operating income. We ...

Charles Gross

Morningstar | Pharma Organic Growth Reaches 15% in Solid 1Q for Aptar

Aptar started the year on a high note, with organic sales growth of 7% over the prior year, due principally to superb results from its pharma business. Segment income also performed solidly, up just over 12% thanks to the benefit of falling resin prices and a consolidated mix shift toward pharma over its food and beauty segments. Management didn't have any one factor to point to as a driver of outperformance, saying that all business units operated well during the quarter. With our outlook largely unchanged, our fair value estimate remains $89 per share and our narrow moat rating is intact. Af...

Aptargroup Inc: 1 director sold

A director at Aptargroup Inc sold 2,313 shares at 112.126USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board...

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

ValuEngine Rating and Forecast Report for ATR

MarketLine Department

Berry Plastics Group, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Berry Plastics Group, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Berry Plastics Group, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competit...

MarketLine Department

Amcor Limited - Strategy, SWOT and Corporate Finance Report

Summary Amcor Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Scope - Detailed information on Amcor Limited required for business and competitor intelligence needs - A study of the major internal and external factors affecting Amcor Limited in the form of a SWOT analysis - An in-depth view of the business model of Amcor Limited including a breakdown and examination o...

MarketLine Department

Gerresheimer AG - Strategy, SWOT and Corporate Finance Report

Summary Gerresheimer AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Gerresheimer AG (Gerresheimer) manufactures and supplies specialty glass and plastic products primarily for pharmaceutical and healthcare industries. Its product portfolio includes tubular glass, plastic systems and molded glass products such as vials, ampoules, cartridges, glass syringes, g...

MarketLine Department

TriMas Corp - Strategy, SWOT and Corporate Finance Report

Summary TriMas Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights TriMas Corp (TriMas) is a manufacturer of engineered products. The company designs, manufactures, and distributes dispensing systems, fasteners, bolts, engines and replacement parts, compressor and gaskets. The company offers its products to consumer packaging, aerospace and defense, petroleum r...

MarketLine Department

Berry Global Group, Inc. - Strategy, SWOT and Corporate Finance Report

Berry Global Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Berry Global Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Berry Global Group Inc (Berry Global) manufactures and sells plastic consumer packaging, nonwoven specialty materials and engineered materials. Its product portfolio includes stretch and shrink films; institutio...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Despite weakness in a number of Consumer Discretionary stocks, there are a number of names that remain attractive (ex. KBH, PHM, SIX, RRGB, WEN, SHAK, DNKN, and WMT) • The Consumer Staples Sector continues to have a number of leadership names. (ex. HSY, K, SAFM, VGR, and CHD) • Gold remains a leadership area of the market. (ex. RGLD, and NEM) • REITs and Utilities are increasingly moving as market leadership. (ex. OHI, WELL, LTC, DEA, IRT, EQR, UDR, ADC, EXR, CONE, NSA, AMT, NEE, IDA, DUK, and ES)

ResearchPool Subscriptions

Get the most out of your insights

Get in touch